The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of a randomized phase IIb study estimating overall survival of pralatrexate versus erlotinib in platinum-pretreated NSCLC.
J. D. Patel
Research Funding - Allos Therapeutics
C. G. Azzoli
Research Funding - Allos Therapeutics
G. A. Weems
Employment or Leadership Position - Allos Therapeutics
Stock Ownership - Allos Therapeutics
A. Koutsoukos
Employment or Leadership Position - Allos Therapeutics
Stock Ownership - Allos Therapeutics
P. Zatloukal
No relevant relationships to disclose
K. Kelly
Consultant or Advisory Role - Allos Therapeutics